The unique vaccine production platform has been developed
The Chumakov Research Center (Polio Institute) has developed a unique biotechnological platform for the production of whole-virion vaccines. Due to the fact that it is based on the existing scientific and production complex, it will be possible to launch large-scale production of the necessary drugs in a short time.
The platform will allow the development and production of whole-virion vaccines, including inactivated variants using a variety of cell cultures, as well as the identification of new viruses, including those at risk of developing into an epidemic. It can also be used to conduct preclinical research, standardize technological processes, industrial scaling and production. An important point is that the development and scaling of this technology can be applied not only in the field of vaccinology, but also in other areas of scientific and technological development.
The Polio Institute has developed three polio vaccines between 2016 and 2023, as well as vaccines against yellow fever and coronavirus infection. Academician A. Ishmukhametov, Director of the M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute), noted that two more vaccines — against tick-borne encephalitis and hemorrhagic fever with renal syndrome, are at the stage of technological readiness.